FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2696-2705 December 27, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text  Full Text Audio PowerPoint Slide Set CME Exam Supplementary Material Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

A 68-year-old man presents with newly diagnosed prostate cancer. Over the past 3 years, his serum prostate-specific antigen (PSA) level has been slowly and steadily increasing (from 4.0 ng per milliliter to 4.3 ng per milliliter to 4.7 ng per milliliter). His digital rectal examination is normal; the prostate volume, estimated by means of ultrasonography, is 48 ml, and a needle-biopsy specimen . . . [Full Text of this Article]

The Clinical Problem

Strategies and Evidence

Evaluation

            Imaging

            Assessment of Life Expectancy

Treatment

            Expectant Management

            Radiation Therapy

            Surgery

Areas of Uncertainty

Guidelines from Professional Societies

Conclusions and Recommendations

Source Information

From the James Buchanan Brady Urological Institute, the Sidney Kimmel Comprehensive Cancer Center, the Department of Urology, Radiation Oncology and Molecular Radiation Sciences, and the Department of Oncology, Johns Hopkins Medical Institutions, Baltimore.

Address reprint requests to Dr. Walsh at the James Buchanan Brady Urological Institute, 600 N. Wolfe St., Phipps 554, Baltimore, MD 21287-2101, or at pwalsh@jhmi.edu.

This article has been cited by other articles:

• Lu-Yao, G. L., Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., DiPaola, R. S., Barry, M. J., Zietman, A., O'Leary, M., Walker-Corkery, E., Yao, S.-L. (2009). Outcomes of Localized Prostate Cancer Following Conservative Management. JAMA 302: 1202-1209 [Abstract] [Full Text]  
• Nanda, A., Chen, M.-H., Braccioforte, M. H., Moran, B. J., D'Amico, A. V. (2009). Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease-Induced Congestive Heart Failure or Myocardial Infarction. JAMA 302: 866-873 [Abstract] [Full Text]  
• Arneth, B. M. (2009). Clinical Significance of Measuring Prostate-Specific Antigen. Lab Med 40: 487-491 [Abstract] [Full Text]  
• Welch, H. G., Woloshin, S., Schwartz, L. M. (2008). The Sea of Uncertainty Surrounding Ductal Carcinoma In Situ--The Price of Screening Mammography. JNCI J Natl Cancer Inst 100: 228-229 [Full Text]